Complete Filing Data
Damora Therapeutics, Inc. reported Stockholders Equity of $240.38 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Damora Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income * | -$209.8M | -$21.4M | -$38.3M | -$61.6M | -$51.8M | -$34.8M | -$36.5M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $705.0K | -$283.0K | $393.0K | $265.0K | -$917.0K | $3.1M | -$806.0K |
| Research And Development Expense | $26.9M | $6.4M | $23.8M | $48.2M | $38.5M | $24.6M | $19.7M |
| Operating Income Loss | -$210.9M | -$22.3M | -$39.9M | -$61.2M | -$52.2M | -$33.6M | $39.0M |
| Operating Expenses | $210.9M | $22.3M | $39.9M | $61.2M | $52.2M | $33.6M | $39.0M |
| Nonoperating Income Expense | $1.1M | $862.0K | $1.6M | -$417.0K | $475.0K | -$1.2M | $2.5M |
| General And Administrative Expense | $9.7M | $10.5M | $12.7M | $13.0M | $13.7M | $9.0M | $2.4M |
| Comprehensive Income Net Of Tax | -$209.1M | -$21.7M | -$37.7M | -$61.5M | -$52.7M | -$31.7M | -$37.3M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $705.0K | -$283.0K | $624.0K | $76.0K | -$994.0K | $3.1M | |
| Interest Income Expense Net | $1.2M | $844.0K | $1.7M | $722.0K | $156.0K | ||
| Other Comprehensive Income Loss Net Of Tax | $705.0K | -$283.0K | $624.0K | $76.0K | -$994.0K | ||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$209.8M | -$21.4M | -$38.3M | ||||
| Restructuring Costs | $0.00 | $968.0K | $3.4M | ||||
| Income Tax Expense Benefit | $50.0K | $41.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$3.1M | -$3.4M | -$2.5M | -$3.9M | -$5.3M | -$5.5M | -$8.1M | -$10.7M | -$13.0M | -$13.7M | -$16.9M | -$16.9M | -$12.7M | -$12.3M | -$13.3M | -$11.7M | -$5.9M | -$5.7M | -$4.1M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $14.0K | $509.0K | $203.0K | $468.0K | -$131.0K | -$86.0K | $127.0K | -$35.0K | $25.0K | -$344.0K | -$719.0K | -$170.0K | -$369.0K | $153.0K | -$524.0K | $2.3M | $15.0K | -$210.0K | -$2.1M |
| Research And Development Expense | $1.4M | $1.5M | $678.0K | $1.1M | $1.8M | $2.5M | $2.6M | $8.1M | $10.4M | $10.5M | $13.7M | $13.2M | $9.7M | $8.6M | $10.0M | $7.7M | $4.5M | $4.7M | $3.7M |
| Operating Income Loss | -$3.2M | -$3.4M | -$2.6M | -$3.8M | -$5.6M | -$5.7M | -$8.6M | -$11.2M | -$13.5M | -$13.6M | -$17.1M | -$16.9M | -$12.9M | -$12.3M | -$13.6M | -$10.2M | -$6.3M | -$5.8M | $4.8M |
| Operating Expenses | $3.2M | $3.4M | $2.6M | $3.8M | $5.6M | $5.7M | $8.6M | $11.2M | $13.5M | $13.6M | $17.1M | $16.9M | $12.9M | $12.3M | $13.6M | $10.2M | $6.3M | $5.8M | $4.8M |
| Nonoperating Income Expense | $23.0K | -$12.0K | $68.0K | -$36.0K | $281.0K | $264.0K | $447.0K | $415.0K | $498.0K | -$108.0K | $234.0K | $1.0K | $243.0K | -$34.0K | $207.0K | -$1.5M | $403.0K | $156.0K | $721.0K |
| General And Administrative Expense | $1.7M | $2.0M | $1.9M | $2.7M | $2.8M | $3.3M | $3.3M | $3.1M | $3.1M | $3.1M | $3.4M | $3.7M | $3.2M | $3.6M | $3.6M | $2.5M | $1.8M | $1.1M | $1.2M |
| Comprehensive Income Net Of Tax | -$3.1M | -$2.9M | -$2.3M | -$3.4M | -$5.5M | -$5.5M | -$8.0M | -$10.8M | -$12.9M | -$14.2M | -$17.7M | -$17.3M | -$13.0M | -$12.1M | -$13.9M | -$9.3M | -$5.9M | -$5.9M | -$6.2M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $14.0K | $509.0K | $203.0K | $468.0K | -$129.0K | -$54.0K | $183.0K | -$10.0K | $117.0K | -$426.0K | -$804.0K | -$375.0K | -$335.0K | $176.0K | -$604.0K | $2.3M | $15.0K | ||
| Interest Income Expense Net | $42.0K | $50.0K | $74.0K | $146.0K | $213.0K | $257.0K | $473.0K | $442.0K | $434.0K | $221.0K | $156.0K | $61.0K | $35.0K | $52.0K | $39.0K | ||||
| Other Comprehensive Income Loss Net Of Tax | $14.0K | $509.0K | $203.0K | $468.0K | -$129.0K | -$54.0K | $183.0K | -$10.0K | $117.0K | -$426.0K | -$804.0K | -$375.0K | -$335.0K | ||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$3.1M | -$3.4M | -$2.5M | -$3.9M | -$5.3M | -$5.5M | -$8.1M | -$10.7M | |||||||||||
| Restructuring Costs | $0.00 | $968.0K | $2.7M | ||||||||||||||||
| Income Tax Expense Benefit | $0.00 | $4.0K | $2.0K | $7.0K | $42.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $240.4M | $15.8M | $32.3M | $61.8M | $117.2M | $165.5M | -$71.1M | -$33.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $257.6M | $14.2M | $21.5M | $32.8M | $62.6M | $163.8M | $11.5M | $31.1M |
| Cash And Cash Equivalents At Carrying Value | $257.6M | $14.2M | $21.5M | $32.8M | $62.6M | $163.6M | $11.3M | |
| Marketable Securities Unrealized Gain Loss | $231.0K | -$259.0K | -$77.0K | |||||
| Retained Earnings Accumulated Deficit | -$487.4M | -$277.5M | -$256.1M | -$217.7M | -$156.1M | -$104.4M | -$69.5M | |
| Prepaid Expense And Other Assets Current | $2.8M | $2.7M | $3.6M | $3.7M | $9.9M | $5.7M | $5.1M | |
| Operating Lease Right Of Use Asset | $68.0K | $73.0K | $247.0K | $810.0K | $834.0K | $885.0K | $298.0K | |
| Liabilities Current | $20.1M | $1.2M | $5.8M | $11.1M | $4.5M | $5.6M | $7.9M | |
| Liabilities And Stockholders Equity | $260.5M | $17.1M | $38.2M | $73.2M | $122.2M | $171.6M | $56.6M | |
| Liabilities | $20.1M | $1.3M | $5.9M | $11.4M | $5.0M | $6.1M | $8.1M | |
| Assets Current | $260.4M | $16.8M | $36.8M | $63.9M | $110.1M | $169.3M | $56.1M | |
| Assets | $260.5M | $17.1M | $38.2M | $73.2M | $122.2M | $171.6M | $56.6M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $802.0K | $97.0K | $380.0K | -$244.0K | -$320.0K | $674.0K | -$2.5M | |
| Accrued Liabilities And Other Liabilities | $2.4M | $820.0K | $4.1M | $7.8M | $3.0M | $2.7M | $4.6M | |
| Accounts Payable Current | $444.0K | $377.0K | $1.7M | $3.4M | $1.5M | $2.9M | $3.3M | |
| Operating Lease Right Of Use Asset Amortization Expense | $12.0K | $160.0K | $561.0K | $448.0K | $421.0K | $188.0K | $111.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $242.7M | -$7.0M | -$11.7M | -$30.0M | -$100.4M | $149.2M | -$19.7M | |
| Other Assets Noncurrent | $0.00 | $163.0K | $1.1M | $2.3M | $2.0M | $1.2M | ||
| Operating Lease Liability Noncurrent | $53.0K | $61.0K | $66.0K | $328.0K | $448.0K | $541.0K | $211.0K | |
| Accretion Of Lease Liability | $6.0K | $10.0K | $46.0K | $58.0K | $75.0K | $55.0K | ||
| Property Plant And Equipment Net | $36.0K | $57.0K | $78.0K | $357.0K | $203.0K | |||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $75.0K | $488.0K | $411.0K | $713.0K | $391.0K | |||
| Accretion Amortization Of Discounts And Premiums Investments | -$70.0K | $431.0K | -$566.0K | -$1.1M | ||||
| Marketable Securities Current | $11.7M | $27.4M | $37.6M | |||||
| Marketable Securities Noncurrent | $5.8M | $9.0M | ||||||
| Restricted Cash Noncurrent | $254.0K | $231.0K | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | $1.3M | $1.4M | $119.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $8.0M | $11.0M | $13.7M | $20.9M | $23.6M | $28.2M | $37.4M | $43.7M | $50.3M | $72.7M | $85.1M | $101.3M | $129.6M | $141.4M | $152.6M | -$91.7M | -$82.6M | -$77.0M | -$48.1M | -$41.9M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $7.6M | $10.2M | $11.9M | $19.7M | $22.9M | $21.1M | $23.1M | $23.0M | $25.1M | $28.3M | $29.8M | $45.4M | $66.2M | $68.6M | $74.5M | $85.6M | $36.1M | $43.0M | $14.9M | |
| Cash And Cash Equivalents At Carrying Value | $7.6M | $10.2M | $11.9M | $19.7M | $22.9M | $21.1M | $23.1M | $23.0M | $25.1M | $28.3M | $29.8M | $45.4M | $66.2M | $68.6M | $74.3M | $85.3M | $35.8M | $42.8M | $14.7M | |
| Marketable Securities Unrealized Gain Loss | $2.0K | $32.0K | $56.0K | $25.0K | $92.0K | -$82.0K | -$155.0K | -$205.0K | $34.0K | $23.0K | -$80.0K | |||||||||
| Retained Earnings Accumulated Deficit | -$286.6M | -$283.5M | -$280.1M | -$270.8M | -$266.9M | -$261.6M | -$249.6M | -$241.5M | -$230.7M | -$203.7M | -$189.9M | -$173.1M | -$142.7M | -$130.0M | -$117.7M | -$92.8M | ||||
| Prepaid Expense And Other Assets Current | $2.2M | $2.8M | $3.0M | $1.5M | $2.3M | $3.4M | $2.9M | $3.2M | $3.9M | $2.1M | $3.2M | $3.4M | $4.9M | $5.9M | $6.6M | $5.3M | ||||
| Operating Lease Right Of Use Asset | $72.0K | $75.0K | $73.0K | $32.0K | $76.0K | $152.0K | $453.0K | $633.0K | $704.0K | $852.0K | $554.0K | $702.0K | $940.0K | $1.1M | $933.0K | $905.0K | ||||
| Liabilities Current | $2.6M | $2.6M | $1.6M | $2.4M | $3.7M | $4.3M | $12.6M | $14.9M | $14.1M | $8.9M | $7.5M | $7.2M | $5.7M | $4.8M | $5.5M | $8.3M | ||||
| Liabilities And Stockholders Equity | $10.7M | $13.7M | $15.4M | $23.4M | $27.3M | $32.5M | $50.0M | $58.8M | $64.6M | $82.0M | $92.9M | $108.9M | $135.9M | $146.8M | $158.7M | $98.2M | ||||
| Liabilities | $2.7M | $2.7M | $1.7M | $2.4M | $3.7M | $4.3M | $12.7M | $15.1M | $14.3M | $9.3M | $7.8M | $7.6M | $6.3M | $5.4M | $6.1M | $8.9M | ||||
| Assets Current | $9.8M | $13.0M | $14.9M | $21.2M | $25.2M | $30.5M | $47.1M | $55.4M | $57.1M | $71.2M | $82.2M | $97.0M | $107.0M | $107.7M | $116.9M | $96.1M | ||||
| Assets | $10.7M | $13.7M | $15.4M | $23.4M | $27.3M | $32.5M | $50.0M | $58.8M | $64.6M | $82.0M | $92.9M | $108.9M | $135.9M | $146.8M | $158.7M | $98.2M | ||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $823.0K | $809.0K | $300.0K | $665.0K | $197.0K | $326.0K | $46.0K | -$137.0K | -$127.0K | -$1.9M | -$1.5M | -$695.0K | -$89.0K | $246.0K | $70.0K | -$315.0K | ||||
| Accrued Liabilities And Other Liabilities | $2.1M | $1.9M | $1.2M | $1.9M | $3.0M | $2.7M | $8.1M | $9.3M | $10.5M | $7.0M | $4.7M | $4.0M | $3.8M | $3.2M | $3.8M | $3.8M | ||||
| Accounts Payable Current | $520.0K | $756.0K | $354.0K | $503.0K | $724.0K | $1.7M | $4.5M | $5.6M | $3.6M | $1.9M | $2.8M | $3.2M | $2.0M | $1.6M | $1.8M | $4.5M | ||||
| Operating Lease Right Of Use Asset Amortization Expense | $3.0K | $93.0K | $121.0K | $110.0K | $97.0K | $25.0K | ||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$2.4M | -$286.0K | -$7.7M | -$17.0M | -$88.8M | $31.7M | ||||||||||||||
| Other Assets Noncurrent | $837.0K | $542.0K | $317.0K | $2.1M | $2.0M | $1.7M | $2.4M | $2.5M | $2.5M | $2.8M | $3.0M | $2.8M | $1.4M | $1.1M | $1.1M | |||||
| Operating Lease Liability Noncurrent | $57.0K | $60.0K | $60.0K | $112.0K | $206.0K | $234.0K | $440.0K | $305.0K | $402.0K | $511.0K | $635.0K | $544.0K | $589.0K | |||||||
| Accretion Of Lease Liability | $1.0K | $4.0K | $16.0K | $16.0K | $19.0K | |||||||||||||||
| Property Plant And Equipment Net | $41.0K | $47.0K | $52.0K | $62.0K | $67.0K | $73.0K | $125.0K | $328.0K | $345.0K | $338.0K | $205.0K | $238.0K | $214.0K | $176.0K | $63.0K | |||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $449.0K | $409.0K | $409.0K | $161.0K | $420.0K | $252.0K | ||||||||||||||
| Accretion Amortization Of Discounts And Premiums Investments | $12.0K | $154.0K | -$264.0K | $92.0K | ||||||||||||||||
| Marketable Securities Current | $6.1M | $21.1M | $29.2M | $28.2M | $40.7M | $49.2M | $48.2M | $36.0M | $33.2M | $36.1M | ||||||||||
| Marketable Securities Noncurrent | $4.0M | $6.8M | $6.9M | $8.2M | $25.5M | $35.9M | $38.6M | |||||||||||||
| Restricted Cash Noncurrent | $197.0K | $241.0K | $231.0K | $226.0K | $223.0K | |||||||||||||||
| Temporary Equity Carrying Amount Attributable To Parent | $1.3M | $1.3M | $1.4M | $181.0M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$6.7M | -$18.6M | -$36.9M | -$42.9M | -$52.3M | -$38.2M | -$19.3M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $138.0K | -$954.0K | -$65.0K | -$6.2M | $4.2M | $596.0K | $1.2M |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $1.1M | -$3.1M | -$3.3M | $4.7M | $274.0K | -$2.1M | $1.6M |
| Increase Decrease In Accounts Payable | $51.0K | -$1.3M | -$1.6M | $1.8M | -$1.3M | -$477.0K | $1.9M |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $705.0K | -$317.0K | $384.0K | $264.0K | -$917.0K | $3.1M | $46.0K |
| Increase Decrease In Operating Lease Liabilities | -$20.0K | -$170.0K | -$600.0K | -$523.0K | -$513.0K | -$213.0K | |
| Share Based Compensation | $998.0K | $3.2M | $5.4M | $5.6M | $4.5M | $982.0K | |
| Increase Decrease In Other Noncurrent Assets | -$166.0K | -$970.0K | -$1.1M | $257.0K | $866.0K | $1.2M | |
| Net Cash Provided By Used In Investing Activities | -$17.4M | $11.7M | $22.3M | $12.4M | -$48.0M | -$326.0K | |
| Proceeds From Sale And Maturity Of Marketable Securities | $11.7M | $48.2M | $57.4M | $36.4M | |||
| Payments To Acquire Available For Sale Securities Debt | $25.9M | $44.9M | $84.2M | ||||
| Net Cash Provided By Used In Financing Activities | $266.8M | $2.9M | $507.0K | $187.4M | |||
| Payments To Acquire Property Plant And Equipment | $196.0K | $223.0K | |||||
| Proceeds From Issuance Of Common Stock | $2.9M | $507.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$2.4M | -$5.9M | -$9.1M | -$6.8M | -$14.2M | -$8.0M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $323.0K | -$252.0K | $194.0K | -$6.5M | $855.0K | -$309.0K |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $377.0K | -$1.4M | $2.8M | $1.1M | $1.0M | -$890.0K |
| Increase Decrease In Accounts Payable | -$23.0K | -$37.0K | $200.0K | $1.7M | -$1.1M | -$1.7M |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $203.0K | -$88.0K | $19.0K | -$171.0K | -$604.0K | -$210.0K |
| Increase Decrease In Operating Lease Liabilities | -$5.0K | -$92.0K | -$148.0K | -$114.0K | -$119.0K | -$31.0K |
| Share Based Compensation | $179.0K | $1.4M | $1.4M | $1.4M | $1.0M | |
| Increase Decrease In Other Noncurrent Assets | $151.0K | $582.0K | $212.0K | $770.0K | $822.0K | |
| Net Cash Provided By Used In Investing Activities | $5.7M | $1.4M | -$10.2M | -$74.6M | ||
| Proceeds From Sale And Maturity Of Marketable Securities | $5.7M | $14.1M | $16.2M | |||
| Payments To Acquire Available For Sale Securities Debt | $12.8M | $26.4M | $74.6M | |||
| Net Cash Provided By Used In Financing Activities | $23.0K | $39.7M | ||||
| Payments To Acquire Property Plant And Equipment | $43.0K | $65.0K | ||||
| Proceeds From Issuance Of Common Stock | $23.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Diluted EPS * | $3.98 | -$18.53 | -$36.08 | -$2.43 | -$2.05 | -$7.62 | -$161.82 |
| Common Stock Shares Authorized | 500.0M | 500.0M | 300.0M | 300.0M | 300.0M | 300.0M | 5.4M |
| Common Stock Shares Outstanding | 1.6M | 1.3M | 1.1M | 25.7M | 25.3M | 25.3M | 260.0K |
| Common Stock Shares Issued | 1.6M | 1.3M | 1.1M | 25.7M | 25.3M | 25.3M | 260.0K |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Weighted Average Number Of Shares Outstanding Basic | 1.4M | 1.2M | 1.1M | 25.4M | 25.3M | ||
| Weighted Average Number Of Diluted Shares Outstanding | 1.4M | 1.2M | 1.1M | 25.4M | 25.3M | ||
| Earnings Per Share Basic | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 | ||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 0.00 | ||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | ||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 25.3M | 4.6M | 260.0K | ||||
| Temporary Equity Shares Outstanding | 159.00 | 161.00 | 0.00 | ||||
| Temporary Equity Shares Issued | 159.00 | 161.00 | 0.00 | ||||
| Temporary Equity Shares Authorized | 10.0M | 10.0M | 10.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$2.36 | -$2.60 | -$1.92 | -$3.39 | -$4.92 | -$5.05 | -$7.50 | -$0.41 | -$0.51 | -$0.54 | -$0.67 | -$0.67 | -$0.50 | -$0.49 | -$0.53 | -$55.25 | -$22.83 | -$21.83 | -$21.18 | |
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | ||||
| Common Stock Shares Outstanding | 1.3M | 1.3M | 1.3M | 1.3M | 27.1M | 27.1M | 27.1M | 27.0M | 25.7M | 25.6M | 25.3M | 25.3M | 25.3M | 25.3M | 25.3M | 260.0K | ||||
| Common Stock Shares Issued | 1.3M | 1.3M | 1.3M | 1.3M | 27.1M | 27.1M | 27.1M | 27.0M | 25.7M | 25.6M | 25.3M | 25.3M | 25.3M | 25.3M | 25.3M | 260.0K | ||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Weighted Average Number Of Shares Outstanding Basic | 1.3M | 1.3M | 1.3M | 1.1M | 1.1M | 1.1M | 1.1M | 26.4M | 25.7M | 25.5M | 25.3M | 25.3M | 25.3M | |||||||
| Weighted Average Number Of Diluted Shares Outstanding | 1.3M | 1.3M | 1.3M | 1.1M | 1.1M | 1.1M | 1.1M | 26.4M | 25.7M | 25.5M | 25.3M | 25.3M | 25.3M | |||||||
| Earnings Per Share Basic | $-2.36 | $-2.60 | $-1.92 | $-3.39 | $-4.92 | $-5.05 | $-7.50 | $-0.41 | $-0.51 | $-0.54 | $-0.67 | $-0.67 | $-0.50 | |||||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 25.3M | 25.3M | 25.3M | 25.3M | 25.3M | 260.0K | 260.0K | 260.0K | 260.0K | |||||||||||
| Temporary Equity Shares Outstanding | 159.00 | 159.00 | 161.00 | |||||||||||||||||
| Temporary Equity Shares Issued | 159.00 | 159.00 | 161.00 | |||||||||||||||||
| Temporary Equity Shares Authorized | 10.0M | 10.0M | 10.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Foreign Currency Transaction Gain Loss Before Tax | -$84.0K | $18.0K | -$197.0K | -$1.1M | $319.0K | -$1.2M | $551.0K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $998.0K | $3.2M | $5.4M | $5.6M | $4.5M | $1.0M | |
| Depreciation | $22.0K | $21.0K | $269.0K | $42.0K | $20.0K | ||
| Additional Paid In Capital | $310.7M | $291.9M | $288.0M | $279.7M | $273.7M | $269.2M | $826.0K |
| Stock Issued During Period Value New Issues | $2.9M | $507.0K | $86.4M | ||||
| Stock Issued During Period Net Of Issuance Costs | $200.0K | $200.0K | |||||
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | $39.0K | $93.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foreign Currency Transaction Gain Loss Before Tax | -$19.0K | -$62.0K | -$6.0K | -$182.0K | $68.0K | $7.0K | -$26.0K | -$27.0K | $64.0K | -$329.0K | $148.0K | -$60.0K | $208.0K | -$86.0K | $168.0K | -$1.5M | $403.0K | $156.0K | $337.0K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $164.0K | $172.0K | $179.0K | $681.0K | $891.0K | $1.4M | $1.5M | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $1.2M | $987.0K | $1.0M | $134.0K | $401.0K | ||
| Depreciation | $6.0K | $6.0K | $5.0K | $6.0K | $5.0K | $5.0K | $211.0K | $17.0K | $18.0K | $6.0K | $7.0K | $8.0K | $8.0K | $2.0K | $2.0K | ||||
| Additional Paid In Capital | $292.5M | $292.3M | $292.1M | $291.1M | $290.3M | $289.4M | $286.9M | $285.3M | $281.2M | $278.3M | $276.5M | $275.1M | $272.4M | $271.2M | $270.2M | $1.4M | |||
| Stock Issued During Period Value New Issues | $171.0K | $2.7M | $23.0K | $420.0K | $23.0K | ||||||||||||||
| Stock Issued During Period Net Of Issuance Costs | $100.0K | $100.0K | $100.0K | ||||||||||||||||
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | $9.0K | $29.0K | $81.0K | $5.0K |
Most recent annual filing with the SEC: March 19, 2026
Data sourced from SEC EDGAR public filings as of August 4, 2026.